Who is sponsoring NCT06309212?

NCT06309212 is sponsored by Acibadem University.

What drugs are being tested in NCT06309212?

Interventions in NCT06309212: Observation.

What condition does NCT06309212 study?

NCT06309212 studies The Prevalance of HMPV After COVID-19 Pandemic, The Importance of Accurate Diagnosis for HPMV.

Is NCT06309212 still recruiting?

NCT06309212 is currently completed. Last updated 13 March 2024.

Last reviewed 2024-03-13 · How we verify

NCT06309212

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessing the Impact of COVID-19 on HMPV Incidence and Severity Among Adults

Completed Last updated 13 March 2024

What this trial tests

trial testing Observation in The Prevalance of HMPV After COVID-19 Pandemic in 2,197 participants. Completed in 30 January 2024.

Timeline

15 December 2023

Primary endpoint
30 December 2023

30 January 2024

Quick facts

Lead sponsor	Acibadem University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2,197
Start date	15 December 2023
Primary completion	30 December 2023
Estimated completion	30 January 2024
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Observation

Conditions studied

The Prevalance of HMPV After COVID-19 Pandemic — all drugs for The Prevalance of HMPV After COVID-19 Pandemic →
The Importance of Accurate Diagnosis for HPMV — all drugs for The Importance of Accurate Diagnosis for HPMV →

Sponsor

Acibadem University

Who can join

Adults 18 to 100, any sex, with The Prevalance of HMPV After COVID-19 Pandemic or The Importance of Accurate Diagnosis for HPMV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Human metapneumovirus (HMPV) is primarily recognized as a childhood pathogen, but its impact on adults remains largely underestimated. This study investigates the prevalence, clinical characteristics, and post-COVID-19 trends of HMPV infection among adults in Istanbul, Turkey.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Observation

Trials testing the same drug.

NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting
NCT07563088 — SPARE-1st: Surgery Alone vs Surgery Plus Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma · not yet recruiting
NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting
NCT07457099 — Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral a · not yet recruiting
NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting

Other Acibadem University trials

Trials by the same sponsor.

NCT07481864 — The Effect of Early-Phase Graded Motor Imagery Following Massive Rotator Cuff Repair. · NA · not yet recruiting
NCT07488377 — Turkish Cognitive Self-Efficacy Questionnaire in Parkinson's Disease · not yet recruiting
NCT07488364 — Determinants of Physical Frailty in Parkinson's Disease: A Multi-Factorial Analysis · not yet recruiting
NCT07488351 — "Self-Compassion and Self-Efficacy in Parkinson's Disease: Associations With Symptoms, Function, and Quality of Life" · not yet recruiting
NCT07413185 — Relationship Between the Severity of Sleep Deprivation in the First 48 Hours Postpartum, Breastfeeding Motivation, and B · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06309212 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Acibadem University
Last refreshed: 13 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06309212.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing